Harbin Pharmaceutical Group Co Ltd banner

Harbin Pharmaceutical Group Co Ltd
SSE:600664

Watchlist Manager
Harbin Pharmaceutical Group Co Ltd Logo
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Watchlist
Price: 3.67 CNY -0.81% Market Closed
Market Cap: ¥9.2B

Harbin Pharmaceutical Group Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Harbin Pharmaceutical Group Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Revenue
¥15.9B
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
¥15B
CAGR 3-Years
17%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
¥32.6B
CAGR 3-Years
15%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
¥41.2B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
7%
Zhejiang Nhu Co Ltd
SZSE:002001
Revenue
¥22.3B
CAGR 3-Years
12%
CAGR 5-Years
17%
CAGR 10-Years
19%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
¥5.8B
CAGR 3-Years
94%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

Harbin Pharmaceutical Group Co Ltd
Glance View

Market Cap
9.2B CNY
Industry
Pharmaceuticals

Founded amidst the industrial boom of the 1950s, Harbin Pharmaceutical Group Co., Ltd. has evolved into one of China's pharmaceutical giants, headquartered in Harbin, Heilongjiang Province. Historically grounded in traditional Chinese medicine, it has grown into a multifaceted enterprise that blends its cultural heritage with modern pharmaceutical science. Harbin Pharma's journey from its humble beginnings to becoming a household name is marked by its robust research and development efforts, which are key to its operations. The company's vertical integration strategy stretches through the entire pharmaceutical value chain, encompassing research, production, and distribution, thereby optimizing efficiency and maintaining quality control across its vast product lines. This structure not only helps minimize costs but also allows Harbin Pharma to quickly adapt to changes in the healthcare market. The company primarily generates revenue through the production and sale of both prescription and over-the-counter drugs, catering to a diverse array of health needs globally. A significant portion of its income stems from the manufacture of antibiotics, patent drugs, and biological products, though it also maintains a strong presence in the consumer health sector with vitamins and dietary supplements. Strategically, Harbin Pharma leverages its extensive distribution network, one of the largest in China, ensuring that its products reach even the most remote areas. Moreover, the company benefits from partnerships and collaborations with international pharmaceutical companies, which allow it to expand its global footprint and enhance its product offerings. In essence, Harbin Pharmaceutical Group's success is anchored in its adaptive business strategies, commitment to innovation, and ability to navigate the complexities of the rapidly evolving pharmaceutical landscape.

Intrinsic Value
5.94 CNY
Undervaluation 38%
Intrinsic Value
Price ¥3.67

See Also

What is Harbin Pharmaceutical Group Co Ltd's Revenue?
Revenue
15.9B CNY

Based on the financial report for Sep 30, 2025, Harbin Pharmaceutical Group Co Ltd's Revenue amounts to 15.9B CNY.

What is Harbin Pharmaceutical Group Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
0%

Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for Harbin Pharmaceutical Group Co Ltd have been 7% over the past three years , 8% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett